Showing results (391-400 of 400) with videos related to
Sort By:
Pageof 40
You have reached the last page of results.This site can display upto 400 results.
Clinical Immunology (Orlando, Fla.)|December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patientsJ E Janik, L L Miller, W C Kopp, et al.Cancer Journal (Sudbury, Mass.)|July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II studyD L Longo, P L Duffey, J G Gribben, et al.Nature Medicine|September 30, 1999
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphomaM Bendandi, C D Gocke, C B Kobrin, et al.Blood|May 11, 1999
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatinL L Miller, E L Korn, D S Stevens, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancerB D Curti, A C Ochoa, G C Powers, et al.Angiogenesis|January 11, 2023
Endothelial cells require functional FLVCR1a during developmental and adult angiogenesisSara Petrillo, F De Giorgio, F Bertino, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patientsB D Curti, A C Ochoa, W J Urba, et al.Journal of the National Cancer Institute|January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanomaJ E Janik, L L Miller, D L Longo, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinomaR G Fenton, R G Steis, K Madara, et al.Leukemia|December 24, 2014
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocationF Abate, M Todaro, J-A van der Krogt, et al.Pageof 40